Healthcare Industry News: meloxicam
News Release - June 12, 2014
SoluMatrix(R) Meloxicam Demonstrates Significant Efficacy at 30 Percent Lower Doses in the Treatment of OsteoarthritisPhase 3 Data Presented at EULAR 2014
PHILADELPHIA--(Healthcare Sales & Marketing Network)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix® meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo1. These data are being presented at the 2014 European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Paris, France.
“Osteoarthritis is one of the most common causes of disability2, and inadequate pain control can lead to joint stiffness that may impair mobility for patients,” said Dr. Roy Altman, Professor of Medicine in Rheumatology at UCLA and lead study author. “Clinicians have an urgent need for new osteoarthritis treatments that can offer reduced systemic exposure when taken over a long period of time, while also helping to restore some of the loss of function due to the nature of this chronic condition. These data show SoluMatrix® meloxicam represents an important new step forward in fulfilling the unmet need for effective low dose treatment options for osteoarthritis.”
In this Phase 3, multi-center, double-blind and placebo-controlled study, 403 patients aged 40 and older with a clinical diagnosis of OA of the knee or hip were randomized to receive treatment with once-daily SoluMatrix® meloxicam 5 mg, SoluMatrix® meloxicam 10 mg, or placebo. The primary efficacy endpoint of the study was the mean change from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score at week 12. Secondary efficacy endpoints included the Patient Global Impression of Change (PGIC), a patient reported outcome measure, as well as the amount of rescue medication (acetaminophen) used by each patient1.
Results of the study found:
- At week 12, patients treated with SoluMatrix® meloxicam 5 mg (P = 0.0005) and 10 mg (P = 0.0059) achieved significantly greater pain relief as measured by the WOMAC pain subscale score compared with patients receiving placebo1.
- Based on PGIC, significantly more patients reported their condition as “very much improved” or “much improved” versus “much worse” or “very much worse” following SoluMatrix® meloxicam 5 mg (P = 0.0049) or 10 mg (P = 0.0012) treatment compared with placebo1.
- Patients in the SoluMatrix® meloxicam 5 mg (P = 0.006) and 10 mg (P = 0.0013) treatment groups used significantly less rescue medication compared with patients in the placebo group1.
- The most frequently reported adverse events (occurring in > 2 percent of patients) in patients treated with SoluMatrix® meloxicam were diarrhea, headache and nausea1.
About Iroko Pharmaceuticals, LLC
Iroko is a global specialty pharmaceutical company, based in Philadelphia, dedicated to advancing the science of analgesia. The company develops and globally commercializes pharmaceutical products. Iroko is at the forefront of the development of SoluMatrix® NSAIDs – new low dose drug products based on existing NSAIDs – using iCeutica Inc.’s proprietary SoluMatrix Fine Particle Technology™ exclusively licensed to Iroko for NSAIDs. The first SoluMatrix® NSAID is available in pharmacies and a second was recently approved by FDA. For more information, visit www.iroko.com.
SoluMatrix Fine Particle Technology™ is a trademark of iCeutica Inc., and the technology is licensed to Iroko for exclusive use in NSAIDs.
SoluMatrix® is a trademark of iCeutica Pty Ltd and is licensed to Iroko.
1 Altman, R., et. al., Lower-Dose SoluMatrix® meloxicam: Efficacy and Safety in a Phase 3 Study in Adults with Osteoarthritis Pain. Final Poster Presentation for 2014 European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology.
2 Neogi, T., The epidemiology and impact of pain in osteoarthritis, Osteoarthritis and Cartilage, 2013. Pg. 1.
Source: Iroko Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.